Showing results (151-160 of 304) with videos related to
Sort By:
Pageof 31
Nature|August 5, 2026
DCAF11-dependent molecular glue degrader activated by glutathionylationHojong Yoon, Franziska Wachter, Katharine A Barrett, et al.Blood Advances|August 3, 2021
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapyPeter G Miller, Adam S Sperling, Elliott J Brea, et al.Blood|October 12, 2017
SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemiaBrenton G Mar, S Haihua Chu, Josephine D Kahn, et al.Journal of the American Chemical Society|September 28, 2023
Chemical Specification of E3 Ubiquitin Ligase Engagement by Cysteine-Reactive ChemistryRoman C Sarott, Inchul You, Yen-Der Li, et al.Blood Cancer Journal|January 12, 2022
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)Warren Fiskus, Steffen Boettcher, Naval Daver, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2014
Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantationRafael Bejar, Kristen E Stevenson, Bennett Caughey, et al.Blood|June 30, 2018
PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cellsJosephine D Kahn, Peter G Miller, Alexander J Silver, et al.Plos Medicine|July 13, 2006
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasiaYana Pikman, Benjamin H Lee, Thomas Mercher, et al.Blood|August 15, 2013
Diminutive somatic deletions in the 5q region lead to a phenotype atypical of classical 5q- syndromeAdrianna Vlachos, Jason E Farrar, Eva Atsidaftos, et al.The Journal of Clinical Investigation|February 16, 2016
MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1CNan Zhu, Mo Chen, Rowena Eng, et al.Pageof 31